Skip to main content

FY2025 1Q Consolidated Financial Overview

[Based on Japanese GAAP]

Operating Results

Overview of Operating Results

  • Net sales

    17,641 million yen

    YOY 7.9%

  • Operating profit

    1,479 million yen

    YOY (15.9)%

  • Ordinary profit

    1,620 million yen

    YOY (10.6)%

  • Profit attributable to owners of parent

    1,244 million yen

    YOY (2.3)%

  • Earnings per share

    43.88 yen

    YOY (2.4)%

During the first quarter of the consolidated fiscal year, although the domestic economy is expected to recover gradually due to improvements in the employment and income environment and the effects of various policies, the outlook remains uncertain due to downside risks to the economy from the impact of U.S. trade policies and rising raw material and resource prices. In the ethical pharmaceuticals business, which constitutes the core of the Group, the business environment remained severe, partly due to the impact of the annual NHI drug price revisions. However, the Group's net sales increased by 1,289 million yen YoY to 17,641 million yen (up 7.9% YoY) due to the steady performance of the pharmaceutical and veterinary pharmaceutical businesses, as well as the conversion of a Vietnamese pharmaceutical company, an equity method affiliate, into a consolidated subsidiary. On the profit side, however, due to an increase in R&D expenses, operating profit was 1,479 million yen (down 15.9% YoY), ordinary profit was 1,620 million yen (down 10.6% YoY), and profit attributable to owners of parent was 1,244 million yen (down 2.3% YoY).

Segment

Net sales

(Millions of yen)

Segment name 1Q 2Q 3Q Full year
Pharmaceutical business 14,515
Animal health business 1,841
Overseas businesses 1,226
Other businesses 58

(i) Pharmaceutical business

The pharmaceutical business, which focuses on the three fields of internal medicine, obstetrics and gynecology, and urology, showed favorable trends overall despite the impact of the annual NHI drug price revisions. A look at results by product shows that results in the obstetrics and gynecology area were driven by the growth in the uterine fibroid and endometriosis agent RELUMINA (relugolix), to 2,768 million yen (up 4.7% YoY). In addition to these, sales of the dysmenorrhea agent DroEthi (drospirenone/ ethinylestradiol) increased significantly to 2,022 million yen (up 16.0% YoY), following the previous year. In the internal medicine area, sales of the thyroid hormone agent THYRADIN (levothyroxine), our main product in this field, grew to 2,125 million yen (up 2.3% YoY) and those of the poorly absorbable rifamycin antimicrobial agent RIFXIMA (rifaximin) increased to 1,902 million yen (up 15.6% YoY) partly due to the positive revision of the NHI drug price. In the urology field, sales of the LH-RH derivative microcapsule sustained-release agent LEUPRORELIN (leuprorelin) were 962 million yen (down 5.7% YoY).

As a result of the above factors, the segment sales were 14,515 million yen (up 0.2% YoY), and the segment profit was 1,698 million yen (down 15.6% YoY) due to an increase in R&D expenses.

(ii) Animal health business

Sales of the animal health business, which sells products such as veterinary pharmaceuticals and feed additives, were 1,841 million yen (up 2.2% YoY). The segment profit was 128 million yen (up 75.2% YoY).

(iii) Overseas businesses

"Overseas business", a new reportable segment, was added following the consolidation of Ha Tay Pharmaceutical Joint Stock Company, a Vietnamese pharmaceutical company, as a consolidated subsidiary in the previous consolidated fiscal year. For the overseas business, sales were 1,226 million yen and segment profit was 73 million yen.

(iv) Other businesses

Sales of the other businesses, which include clinical testing, medical devices, etc., were 58 million yen (up 0.3% YoY). However, the segment loss was 2 million yen (vs. a loss of 5 million yen in the same period of the previous year).

Financial Position

Overview of Financial Position Summary

  • Total assets

    102,952 million yen

    Change from end of previous fiscal year 2.4%

  • Net assets

    69,231 million yen

    Change from end of previous fiscal year 0.1%

  • Equity ratio

    63.6 %

    Change from end of previous fiscal year (1.4)point

Overview of Financial Position

(Assets)

Total assets at the end of the first quarter of the consolidated fiscal year under review stood at 102,952 million yen, up 2,417 million yen from the end of the previous consolidated fiscal year under review. This figure was due primarily to increases in property, plant and equipment, and investment securities.

(Liabilities)

Total liabilities at the end of the first quarter of the consolidated fiscal year under review stood at 33,721 million yen, up 2,382 million yen from the end of the previous consolidated fiscal year. This figure was due primarily to increases in other in current liabilities, long-term borrowings.

(Net assets)

Total assets at the end of the first quarter of the consolidated fiscal year under review stood at 69,231 million yen, up 35 million yen from the end of the previous consolidated fiscal year. This figure was due primarily to an increase in retained earnings resulting from the recording of profit attributable to owners of parent.

The resulting equity ratio was 63.6%, down 1.4 percentage points from the end of the previous consolidated fiscal year.